Company Overview and Recent Developments
Femasys Inc. (NASDAQ: FEMY) is a biomedical company focused on women’s reproductive health, offering innovative in-office solutions for infertility treatment and non-surgical permanent birth control. Its lead products include FemaSeed® Intratubal Insemination, a novel infertility treatment, and FemBloc® permanent birth control, a non-surgical alternative to tubal ligation (www.streetinsider.com) (www.streetinsider.com). Femasys has begun commercializing these innovations both in the U.S. and internationally – for example, FemBloc received full regulatory approval in Europe, the UK, and New Zealand in 2025 (www.streetinsider.com), and the company has distribution partnerships in Spain and other markets. In the U.S., FemBloc is still in clinical development; the pivotal FINALE trial for FemBloc is ongoing as part of the FDA approval process (www.streetinsider.com). Meanwhile, Femasys is actively marketing FemaSeed (and related diagnostic tools like FemVue® and FemChec®) to fertility clinics, signing partnership deals with major networks of reproductive centers to drive adoption.
Inducement Grant Announcement: In February 2026, Femasys announced it granted stock options to two new non-executive employees as an inducement to join the company (www.streetinsider.com). The inducement grants total 185,000 options with exercise prices of $0.50 and $0.57 per share (equal to FEMY’s closing stock price on each new hire’s start date) (www.streetinsider.com). These options vest over four years and were approved by the Board’s Compensation Committee under Nasdaq Listing Rule 5635(c)(4), which allows equity grants to new employees outside shareholder-approved plans (www.streetinsider.com). Although routine for recruiting purposes, these hires (and their equity incentives) suggest Femasys is bolstering its team – a sign of “new opportunities” ahead. In other words, the company appears to be investing in human capital, potentially to support upcoming commercialization initiatives or R&D milestones. The key question is whether and how these new employees will help translate Femasys’s recent product developments into market success.
Dividend Policy and Yield
Femasys has no dividend history – it has never declared or paid cash dividends on its common stock (www.sec.gov). As an early-stage medical technology company, Femasys instead reinvests any earnings (currently, it has none) back into growing the business. Management has explicitly stated they “intend to retain all future earnings, if any, to finance the growth and development of [the] business”, and do not anticipate paying cash dividends for the foreseeable future (www.sec.gov) (www.sec.gov). Consequently, FEMY’s dividend yield is 0%, and shareholders’ returns depend entirely on stock price appreciation. Traditional REIT metrics like FFO or AFFO are not applicable here, given Femasys’s focus on product development rather than income-generating real estate (and the fact that the company is incurring net losses rather than funds from operations). Investors in FEMY should be seeking capital gains driven by successful product commercialization or strategic breakthroughs, rather than income. This dividend policy is typical for biotech/medtech companies that need to conserve cash for R&D and clinical trials.
Financial Position: Leverage and Debt Maturities
Femasys has financed its operations primarily through equity issuance and convertible debt, rather than traditional bank loans. As of year-end 2024, the company had a significant convertible note outstanding, originating from a late-2023 financing: in November 2023 Femasys issued $6.85 million in senior unsecured convertible notes (with attached warrants) (www.sec.gov). These notes carry a 6% interest rate and were scheduled to mature in 2025 (two years from issuance) if not converted into equity (www.sec.gov). Indeed, the entire $6.85 million principal was due in 2025 absent conversion (www.sec.gov). By December 31, 2024, this note was classified as a current liability of ~$5.4 million (net of unamortized discounts) on Femasys’s balance sheet (last10k.com), reflecting the approach of its maturity. Management indicated intention to repay those 2023 notes by their maturity using proceeds from subsequent financings (www.sec.gov).
In late 2025, Femasys refinanced and added to its debt capacity through a new private placement of convertible notes. In two closings (November 7 and November 26, 2025), the company issued an aggregate $12.0 million of additional senior unsecured convertible notes, again accompanied by multiple series of warrants (www.sec.gov) (www.sec.gov). These 2025 notes have a longer horizon – interest payments extend through November 7, 2027, indicating a maturity around that date (www.sec.gov). The conversion terms allow noteholders to convert into common shares (the notes were initially convertible into roughly 16.38 million shares at issuance) and they came with Series A-1, B-1, and C-1 warrants equal to triple the conversion shares, providing substantial upside if the stock appreciates (www.sec.gov). In effect, this financing could double or triple the share count in the future if the notes and warrants are fully converted/exercised. For now, however, the $12 million raised bolstered Femasys’s cash and enabled the company to retire the 2023 notes on schedule (addressing the near-term maturity) (www.sec.gov).
1) The Eyes & Ears of the Grid — Data Oracles
2) The Digital Bank That Never Closes
3) Internet of AI + Blockchain
Aside from these convertible notes, Femasys carries minimal other debt. It previously had a small traditional note payable (about $0.6 million) that was fully repaid in 2023 (www.sec.gov). The company does utilize operating leases (for facilities/equipment), but these lease liabilities are modest (around $1.5 million long-term as of 2024) (last10k.com). Overall, leverage remains moderate in absolute terms – the convertible notes (which can potentially convert to equity) are the primary form of debt. However, given Femasys’s negative earnings, even servicing a 6% interest rate requires external funding or cash on hand. Interest expense on the 2023 note was about $152k in 2023 (including amortization of discounts) (www.sec.gov), and the new 2025 notes would accrue roughly $0.7–$0.8 million in annual interest. Femasys may have the option to pay interest in kind or at maturity (the 2025 notes’ structure suggests interest might be accrued till 2027) (www.sec.gov), which helps short-term cash flow. But ultimately, unless the notes convert to equity, Femasys would need to repay or refinance them in 2027, making that a key maturity to watch. Investors should monitor the company’s plans for handling that deadline – ideally through successful product launches that enable either conversion (if the stock rises above the conversion price) or refinancing under better terms.
Cash Runway and Coverage of Obligations
As a pre-profit company, Femasys’s ability to cover its costs and obligations hinges on its cash reserves and ongoing capital raises. The company remains deeply in the red: in 2024, Femasys generated $1.63 million in sales revenue but incurred a net loss of $18.8 million (last10k.com). Heavy R&D expenses (over $8 million in 2024) and growing commercial expenses for product launches drive these losses (last10k.com). Not surprisingly, operating cash flow is strongly negative, and internal cash generation is far from covering costs or interest.
At the end of 2024, Femasys had only $3.5 million in cash on its balance sheet (last10k.com) – equivalent to just a few months’ worth of operating expenses. In fact, the auditors/management had raised “going concern” considerations before, though an improved cash position in late 2023 temporarily alleviated imminent doubts (www.sec.gov). To extend its runway, Femasys raised an additional ~$5.4 million in early 2025 (likely through at-the-market equity sales or a small offering) (last10k.com). Even with that infusion, the company projected that it only had sufficient funds to operate until the third quarter of 2025 (last10k.com). This underscores the continuous need for financing – essentially, Femasys must repeatedly tap investors to “cover” its cash burn and obligations. Indeed, in the second half of 2025 the company executed two major financings: an $8.0 million public equity offering in August and the $12.0 million convertible note issuance in November (detailed above). These moves have replenished the coffers and likely funded the company into 2026. For example, the November 2025 $12M raise was partly earmarked to pay off the 2023 notes due in 2025 and otherwise for general working capital (www.sec.gov), ensuring debt obligations were met.
Interest coverage (EBIT/interest) is currently not a meaningful metric for Femasys since EBIT is deeply negative. In practical terms, interest on the debt is being paid out of the cash raised from financing activities, not from earnings. The company’s strategy is to finance operations through a combination of available cash, future equity/debt raises, and any incremental revenue from product sales (www.sec.gov). Management is optimistic that growing FemaSeed and FemBloc sales will contribute some cash flow, but acknowledges that external funding will remain necessary to support R&D (especially the U.S. FemBloc trial) (www.sec.gov). Investors should therefore expect further dilution or debt if the pipeline progress doesn’t soon translate into substantially higher revenues. A positive note is that Femasys has kept its liabilities relatively low outside of convertible notes, so it doesn’t face near-term creditor pressure aside from those notes. The key coverage question is whether the company can advance its products to a point of self-sustaining cash flow before the financing window closes – a typical high-risk/high-reward scenario in biotech/medtech.
Share Dilution and Valuation Considerations
Frequent equity issuance has significantly diluted Femasys’s shareholders, which in turn pressures the stock’s valuation. Share count has risen dramatically: for instance, outstanding common shares nearly doubled from ~11.9 million at the end of 2022 to ~21.7 million by the end of 2023 (www.sec.gov). This was due to financing activities (such as at-the-market stock sales and warrant exercises in 2023) and reflects the company’s need for capital. The trend continued in 2024-2025. In August 2025, Femasys sold 10.43 million new shares (and issued an equivalent ~11.75 million in pre-funded warrants) in a public offering at $0.36 per share (www.globenewswire.com) – a steep discount that was necessary to raise $8 million in gross proceeds. Additionally, that deal came with 22.18 million five-year warrants at a $0.36 strike (effectively one warrant for each share/pre-funded share sold) (www.globenewswire.com). Then, in November 2025, the $12 million private placement introduced another layer of dilution: the notes thereunder could convert into roughly 16.38 million shares, and the investors received three tranches of warrants (A-1, B-1, C-1) for an additional 16.38 million shares each (www.sec.gov). If all those warrants were exercised and notes converted, it would add on the order of 65+ million shares down the road. While not all of this potential dilution will necessarily materialize (conversion depends on share price performance, and warrants have a five-year window), the overhang is substantial. This dilutive financing strategy is a red flag for equity holders, as it can cap share price upside (large warrant holders may sell into any rally) and means existing holders end up owning a smaller slice of the company’s future profits.
FEMY’s stock price reflects these challenges. As of late February 2026, the stock trades around $0.57 per share (www.streetinsider.com) – deep in penny-stock territory after a long decline from its IPO price of $13 in 2021. At $0.57, Femasys’s market capitalization is only on the order of ~$20–25 million (depending on how many post-2024 shares/warrants are counted), which is modest for a company with two FDA-cleared products (FemaSeed, FemVue) and a late-stage candidate like FemBloc. In terms of valuation multiples, any traditional metric must be taken with caution due to the tiny revenue base and negative earnings. For example, using 2024 revenues of $1.63 million (last10k.com), the stock trades at roughly 14× trailing sales – a high price-to-sales ratio on the surface. However, investors are valuing the potential market for Femasys’s products rather than its current sales. If FemBloc and FemaSeed achieve widespread adoption, future revenue could increase dramatically, which would make the current market cap appear low. On the other hand, with net losses approaching $19 million/year (last10k.com), price-to-earnings is not meaningful (the P/E is negative). Another way to look at valuation is enterprise value relative to assets: Femasys’s book value was about $2.3 million as of Dec 2024 (last10k.com), so the stock trades at a multiple of book (reflecting the intangible value of its IP and pipeline). At the current share price, the market is clearly assigning speculative value primarily to FemBloc’s promise and the fertility portfolio’s growth, while heavily discounting for execution risks and dilution. It’s also worth noting that at ~$0.50–$0.60 per share, Femasys is at risk of Nasdaq non-compliance again – the stock is below the $1.00 minimum bid price requirement. Management navigated this issue once in 2023 (the company temporarily regained compliance after a brief rally above $1 (ir.femasys.com)), but if the stock does not organically recover, a reverse stock split might become necessary to maintain the Nasdaq listing. This potential outcome can weigh on valuation as well, since reverse splits of penny stocks often precede further price weakness.
Peer Comparison: There are few direct public comps in Femasys’s niche (women’s infertility and non-surgical contraception devices). Many fertility treatment companies are private or part of larger firms. One could loosely compare Femasys to other micro-cap medtech innovators – these often trade at high multiples of current revenue, because investors are valuing pipeline potential. In Femasys’s case, the approximately ~$20M enterprise value (net of recent cash raises) is relatively low in absolute terms, but it’s commensurate with the early stage and heavy cash burn. If we contrast this with more established medtech companies (which might trade at 4–6× sales or 20× earnings), FEMY looks cheap by the price tag – yet it is expensive relative to its tiny revenue and significant uncertainty. The analyst coverage is sparse; notably, one source lists an “Overall Analyst Rating” for FEMY as “Sell”, indicating at least one covering analyst has a bearish stance (www.streetinsider.com). This suggests Wall Street’s sentiment is cautious, likely due to the near-term need for capital and unproven commercial uptake. In summary, Femasys’s valuation reflects a high-risk, high-reward profile: the upside is that successful clinical results and market traction could rerate the stock much higher, but the downside is that ongoing dilution and cash burn could erode shareholder value further if milestones aren’t met.
Key Risks and Red Flags
Investing in Femasys entails significant risks, typical for a small-cap biotech/medtech. Below are some of the major risks and red flags to consider:
– Continued Losses and Cash Burn: Femasys is not yet profitable and incurs substantial losses each year (nearly $19 million net loss in 2024 (last10k.com)). It must keep spending on R&D (e.g. the FemBloc trial) and on building commercial infrastructure, which will likely continue to outstrip revenue for the next few years. There is a risk the company will run out of cash if it fails to raise additional funds or if trials become more costly, potentially forcing cutbacks or distress financing.
– Dilution and Shareholder Value Erosion: The company’s strategy of serial equity and warrant issuances poses a threat to existing shareholders. The share count has ballooned through offerings (doubling from 2022 to 2023 (www.sec.gov), and set to expand further with 2025 issuances), which dilutes each shareholder’s ownership. Numerous warrants outstanding could exert downward pressure on the stock price if exercised and sold. This dilution can be viewed as a red flag because it suggests that even if the business succeeds, current shareholders might only capture a fraction of the eventual value. Investors should monitor Femasys’s financing announcements closely – the terms of future raises (pricing, warrant coverage) will signal the level of dilution risk.
– Regulatory and Clinical Development Risk: Femasys’s flagship FemBloc system still needs FDA approval. While FemBloc has shown promising trial results and obtained European approval, the ongoing U.S. FINALE trial must demonstrate safety and efficacy to the FDA’s satisfaction (www.streetinsider.com). Clinical trials carry the risk of delays, failures, or unforeseen safety issues. Any setback in FemBloc’s trial (or in FemSeed’s post-market studies) could materially derail the company’s plans. Even outside the U.S., regulatory hurdles exist – for instance, obtaining CE Mark was achieved, but ensuring compliance with evolving EU medical device regulations will be an ongoing process. Product approval risk remains high until FemBloc clears the FDA; this is a binary catalyst that could dramatically swing the stock either way.
– Market Adoption and Commercial Risk: Gaining regulatory approvals is only half the battle; the other half is convincing physicians and patients to use Femasys’s products. Traditional infertility treatments (like IVF or IUI) and surgical tubal ligation are well-established. Femasys must educate and persuade practitioners to adopt FemaSeed and FemBloc. Early indications (e.g., initial orders for FemaSeed in Spain (last10k.com) (last10k.com), and partnerships with fertility clinic chains in the U.S.) are positive, but will the uptake be broad enough to generate significant revenue? If sales grow slower than expected, the company’s financial situation could worsen. Reimbursement by insurance is another factor – if procedures using Femasys’s devices aren’t adequately reimbursed, that could hinder adoption. In short, there is significant execution risk on the commercial front.
– Nasdaq Compliance and Liquidity: At the current share price below $1, Femasys runs the risk of again falling out of compliance with Nasdaq’s minimum bid price rule. It already received a deficiency notice in mid-2023 when the stock traded under $1 (ir.femasys.com), though it narrowly regained compliance by later that year (ir.femasys.com) (ir.femasys.com). If FEMY cannot maintain a $1+ share price in the coming months, the company may face delisting or be forced to do a reverse stock split to cure the deficiency. A reverse split could be a red flag as well – while it would technically boost the stock price, it doesn’t fix underlying issues and often precedes further declines. Losing the Nasdaq listing would severely hurt share liquidity and access to capital. Thus, share price stability is a risk factor in itself.
– Balance Sheet Strain and Debt Obligations: While Femasys has no large bank loans, it does carry the convertible notes described earlier. If the stock remains low and noteholders choose not to convert, the company will face a lump-sum debt repayment of $12+ million in late 2027 (www.sec.gov). Femasys will need to either refinance that or have sufficient cash by then – not a trivial task given the current burn rate. There’s a risk that as maturity approaches, if the outlook is uncertain, the company could have to refinance on unfavorable terms (e.g. even more dilutive convertibles or high-interest debt). Interest rate risk is relatively low (6% fixed on current notes (www.sec.gov)), but overall credit risk is high because the company’s solvency hinges on future capital raises.
– Intellectual Property and Competition: Femasys does have a patent portfolio (patents granted or pending for FemaSeed, FemBloc, etc. (ir.femasys.com)), but the longevity of competitive advantage is an open question. Larger medical device companies could develop alternative solutions or even attempt to design around Femasys’s patents. Also, if Femasys’s products gain traction, it might invite competition from new startups in the fertility space. While this risk is not immediately visible, it’s something to watch as the company moves from development to commercialization. Any adverse litigation around IP or appearance of a strong competitor could be a headwind.
– Management and Execution: The company’s leadership, led by founder and CEO Kathy Lee-Sepsick, has steered Femasys through development, but scaling up sales is a new challenge. Any missteps in execution, such as overexpansion, mispricing, or failing to manage the supply chain (note that inventory jumped to $3.0 million in 2024, signifying a build-up for anticipated sales (last10k.com)), could strain finances. So far, there have been no public controversies around management, but investors should keep an eye on governance (e.g., related-party transactions – some of the convertible notes were taken by related parties (www.sec.gov) (www.sec.gov) – and insider stock sales/purchases). On the bright side, insider participation in offerings (e.g., officers bought some shares in the 2025 offering at $0.5151, slightly above the public price (www.globenewswire.com)) can signal confidence, but overall, execution risk remains a factor.
In summary, Femasys carries elevated risk on multiple fronts. The red flags of recurring dilution and cash burn mean the company’s survival is tied to external financing and clinical success. Prospective investors should only invest if they are comfortable with the possibility of losing most of their investment – a common caveat in clinical-stage companies. However, mitigation of these risks (for instance, positive trial results, faster revenue growth, or strategic partnerships) could significantly improve Femasys’s risk profile over time.
Outlook and Open Questions
Despite the challenges, Femasys’s recent developments also present opportunities for growth – and several open questions will determine whether the company can capitalize on them:
– Will new hires drive new opportunities? The very title of this report alludes to the inducement grants for two new employees. While Femasys did not disclose their identities or specific roles, it’s likely these hires are meant to strengthen key areas (such as sales, marketing, or clinical development) at a pivotal time. An open question is how much impact these new team members will have. Will they, for example, accelerate the roll-out of FemaSeed in fertility clinics or improve the execution of the FemBloc trial? The company clearly thought them important enough to issue a special equity grant as a hiring incentive (www.streetinsider.com). Investors will want to watch for any commentary from management about expansion of the sales force or R&D capabilities attributable to these hires, to gauge if the “new opportunities” are materializing.
– Can FemaSeed gain significant traction in the fertility market? Femasys has reported that FemaSeed (an at-home insemination alternative to intrauterine insemination) achieved higher pregnancy rates than traditional IUI in trials (www.streetinsider.com). It has secured partnerships with major fertility clinic networks (e.g. CNY Fertility, Boston IVF, HRC Fertility) to offer FemaSeed (last10k.com) (last10k.com). The open question is how quickly these partnerships will translate into revenue growth. 2024 saw Femasys’s sales rise ~52% to $1.63 million (last10k.com), which is encouraging yet still a small base. Will 2025 or 2026 show an inflection in adoption? Key indicators to watch include the number of clinics adopting FemaSeed, repeat orders (the company noted a second order from a Spanish distributor after initial success (last10k.com)), and any updates on insurance reimbursement for the FemaSeed procedure. The trajectory of FemaSeed uptake will heavily influence Femasys’s financial outlook in the near term.
– How will FemBloc’s journey unfold? FemBloc is arguably the transformative product in Femasys’s portfolio – a non-surgical permanent birth control could address a large global need. With European approval in hand (as of mid-2025) (www.streetinsider.com), a critical question is whether FemBloc can start generating overseas revenue while U.S. approval is pending. The company has inked a strategic distribution deal in Europe (Spain) and presumably will seek others, but what is the timeline to convert those into sales? Additionally, the U.S. FINALE trial’s progress is an open question: Femasys hasn’t publicly given a completion date. Investors should watch for updates on enrollment completion or interim results. A successful pivotal trial could lead to an FDA submission, potentially by late 2026 or 2027 – but any delays would push that timeline out. Moreover, will Femasys need a partner for U.S. commercialization of FemBloc? Launching a new contraceptive product nationwide could be resource-intensive. It remains to be seen if Femasys will continue solo or team up with a larger medtech or women’s health company to co-market FemBloc once approved. Such a partnership could bring non-dilutive funding and marketing muscle (a positive), though it might come at the cost of sharing future economics.
– Is the current funding enough to reach key milestones? After the late-2025 financings, Femasys likely has a cash cushion. But open questions remain on the cash runway. The company estimated in early 2025 that cash (plus a small raise) would last to Q3 2025 (last10k.com); with the subsequent $20M raised, one could project operational funding maybe into late 2026 (depending on burn rate). Will that be sufficient to hit major milestones like completing the FemBloc trial or significantly scaling FemaSeed sales? If not, Femasys might have to raise money again in 2026 – perhaps through another offering or by tapping its shelf registration. The dilution versus milestone timing is a critical balance: every time the company raises capital, it dilutes current shareholders, but not raising would jeopardize its programs. An open question for investors is whether Femasys can secure non-dilutive funding – for instance, grants, upfront payments from a licensing deal, or other creative financings – to bridge the gap. Any such moves would be welcomed and could reduce dilution risk.
– What is the long-term strategic plan? Given Femasys’s size and niche focus, some investors wonder if the company might ultimately be an acquisition target for a larger healthcare firm. The open question is whether management aims to eventually sell the company (if FemBloc proves successful) or to continue as an independent, fully-integrated device company. No clear guidance has been given on this, but it’s something to watch in the coming years. Likewise, how will Femasys prioritize its pipeline beyond FemBloc and FemaSeed? The company has mentioned other products (FemVue, FemChec, FemCath for diagnostics, etc.), but the focus now is on the two main ones. Once FemBloc is (hopefully) approved, does Femasys have additional innovations or improvements in development to sustain growth? Clarity on pipeline depth is an open item that could impact long-term valuation.
In conclusion, Femasys stands at an inflection point. The recent inducement grants and new hires underscore that the company is gearing up for the next phase, be it commercial expansion or late-stage clinical execution. There are tangible opportunities: a growing fertility treatment business and a potentially groundbreaking contraceptive technology. If Femasys executes well – boosting FemaSeed sales and navigating FemBloc to approval – the company’s fortunes could improve markedly, rewarding patient investors. However, numerous questions remain unanswered and risks remain high. The coming 12-24 months will likely be decisive. Investors should keep a close eye on clinical updates, commercial metrics, and financial maneuvers. Each will provide clues as to whether Femasys can indeed spark the “new opportunities” it alludes to, or whether it will stumble under the weight of its challenges. The story of FEMY is one of high stakes in women’s health innovation – with the next chapters to be written by trial results, market reception, and prudent financial stewardship.
Sources:
1. Femasys Inc. press release, “Femasys Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)”, Feb. 27, 2026 – details of stock options granted to new employees (www.streetinsider.com) (www.streetinsider.com). 2. Femasys Inc. 2023 Annual Report on Form 10-K (filed Mar. 2024) – Risk factors and financial statements (no dividends policy, cash burn, convertible notes) (www.sec.gov) (www.sec.gov). 3. Femasys Inc. press release, “Femasys Announces Financial Results for Year Ended Dec 31, 2024”, Mar. 27, 2025 – provides 2024 financials and corporate updates (sales growth, net loss, cash balance) (last10k.com) (last10k.com). 4. GlobeNewswire news release, “Femasys Announces Pricing of $8.0 Million Underwritten Public Offering”, Aug. 25, 2025 – terms of the equity offering at $0.36/share with warrants (www.globenewswire.com). 5. SEC filing (Form S-3), Dec. 2025 – description of November 2025 $12M private placement of convertible notes and warrants (dilution details, note maturity 2027) (www.sec.gov) (www.sec.gov). 6. Femasys Inc. press release, “Femasys Inc. Regains Compliance with Nasdaq Listing Requirements”, Oct. 11, 2023 – information on Nasdaq bid price compliance and prior deficiency (ir.femasys.com) (ir.femasys.com). 7. Femasys Inc. press releases on product developments – “Notice of Allowance for FemaSeed patent” (Jan. 16, 2025) and “FemBloc European approval” (2025) – background on FemBloc and FemaSeed progress (www.streetinsider.com) (www.streetinsider.com). 8. StreetInsider, stock quote for FEMY, Feb. 27, 2026 – recent share price and analyst rating context (www.streetinsider.com). 9. Femasys Inc. SEC filings (10-Qs, 8-Ks) and investor presentations – additional details on financing (e.g., ATM program, use of proceeds) and partnerships (Spain distribution, fertility clinic agreements) (last10k.com) (last10k.com). (Various)
For informational purposes only; not investment advice.
